Colorado Compounding Task Force--Matters Considered During November 2013 Meeting

Colorado Compounding Task Force Meeting
Location:	1560 Broadway, Ste 110D, Denver,CO 80202
Special Meeting:  First Meeting of the Colorado Compounding Task Force
Attachment(s): File Compounding Task Force Nov 2013 Agenda.pdf

California Board of Pharmacy Disciplinary Action from October 2013 to present

here

Pacifica Pharmacy Corp; Thang Tran--No. 2013-01 --precedential decision from California Board of Pharmacy

Precedential Decisions

Under the Administrative Procedure Act (APA) a decision that contains a significant legal or policy determination of general application that is likely to recur may be designated as precedential (see Government Code section 11425.60). Once a decision is designated as precedential, the California State Board of Pharmacy (hereinafter "Board") may rely on it, and parties may cite to such decision in their argument to the Board and courts.

INDEX BY PRECEDENTIAL DECISION NUMBER

Precedential Decision Number	Respondent	Case Numbers
Precedential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran	Case No. 3802 OAH No. 2011010644

INDEX BY SUBJECT MATTER

Basis of Discipline	Respondent	Precedential Decision Number
Standard of Care for Corresponding Responsibility	Pacifica Pharmacy Corp.; Thang Tran	Precedential Decision No. 2013-01

INDEX BY VIOLATION CODE SECTION

Code Sections	Precedential Decision Number	Respondent
Health and Safety Code (H&S)
11153	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
Business and Professions Code (B&P)
1718	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4076(a)(11)	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4081	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4301	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4301(c)	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4301(d)	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4301(j)	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4332	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran
4342	Precdential Decision No. 2013-01	Pacifica Pharmacy Corp.; Thang Tran

Enforcement Action Recently Filed by California Board of Pharmacy Against Pharmacies

Site Licenses

PMC Pharmacy, PHY 48762, Administrative Case AC 4496
Daly City, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

PMC Pharmacy, PHY 50377, Administrative Case AC 4528
Burlingame, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Enforcement Action Recently Filed by California Board of Pharmacy Against Pharmacists

Individual Licenses

Acevedo, Edgar, Applicant, Statement of Issues Case SI 4845
El Monte, CA
Statement of Issues Filed 10/21/2013; Case Pending.
View the accusation

Antognazzi, Brittany, TCH 83750, Administrative Case AC 4777
Berkeley, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Azevedo, Danny Sousa, EXV 21320, Administrative Case AC 4705
Visalia, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Bartee, Gary, RPH 43085, Administrative Case AC 4654
Albany, OR
Accusation Filed 10/23/2013; Case Pending.
View the accusation

Bartlett, Brett, EXC 17211, Administrative Case AC 4779
Grass Valley, CA
Accusation Filed 10/3/2013; Case Pending.
View the accusation

Bechle, Stephanie, TCH 30272, Administrative Case AC 4807
Murrieta, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Carnario, Rosela, TCH 111201, Administrative Case AC 4519
Compton, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Cashpal, Alejandro, TCH 84051, Administrative Case AC 4553
Bakersfield, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Chambers, Brian, RPH 44303, Administrative Case AC 4817
Boise, ID
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Cruz, Sacarias, TCH 111111, Administrative Case AC 4788
Salinas, CA
Accusation Filed 10/3/2013; Case Pending.
View the accusation

Dean, Carl, RPH 37053, Administrative Case AC 4793
Erdenheim, PA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

De Luna, Kimberly, RPH 61593, Administrative Case AC 4528
Daly City, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Dhruv, Ravi, TCH 88006, Administrative Case AC 4401
Los Angeles, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Durden, Jason, TCH 97362, Administrative Case AC 4321
Los Angeles, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Estrada, Ana, TCH 59881, Administrative Case AC 4765
Fresno, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Fulinara, Brandon, TCH 94185, Administrative Case AC 4820
Yorba Linda, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Garcia, Alfonso, Applicant, Statement of Issues Case SI 4834
Imperial Beach, CA
Statement of Issues Filed 10/7/2013; Case Pending.
View the accusation

Garcia, Judith, TCH 112357, Administrative Case AC 4609
Oxnard, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Garcia, Luis, Applicant, Statement of Issues Case SI 4676
San Leandro, CA
Statement of Issues Filed 10/3/2013; Case Pending.
View the accusation

Godbold, Gara, TCH 61514, Administrative Case AC 4640
Pacifica, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Gordon, Michelle, TCH 89567, Administrative Case AC 4730
Salinas, CA
Accusation Filed 10/3/2013; Case Pending.
View the accusation

Governski, Robert, RPH 47933, Administrative Case AC 4725
Telluride, CA
Accusation Filed 10/1/2013; Case Pending.
View the accusation

Gutierrez, Mike Anthony Jr., TCH 67717, Administrative Case AC 4731
San Diego, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Hathaway, Suzanne, TCH 85560, Administrative Case AC 4913
Anderson, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Hoover, Rian, TCH 107183, Administrative Case AC 4719
San Diego, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Jaspal, Jagdip, RPH 55129, Administrative Case AC 4922
Kerman, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Jiang, Barbara, TCH 52663, Administrative Case AC 4496
Daly City, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Johnstone, Crystal, TCH 104667, Administrative Case AC 4902
Paradise, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Knowles, Justin, RPH 63427, Administrative Case AC 4857
Dover NH
Accusation Filed 10/3/2013; Case Pending.
View the accusation

Medina, Elizabeth, Applicant, Statement of Issues Case SI 4843
American Canyon, CA
Statement of Issues Filed 10/21/2013; Case Pending.
View the accusation

Menchaca, Richard, TCH 97927, Administrative Case AC 4900
South Gate, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Mendoza, Corinne, TCH 33289, Administrative Case AC 4824
Angels Camp, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Mobley, Krystle, TCH 69734, Administrative Case AC 4741
Escalon, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Navarrete, Oscar, TCH 102265, Administrative Case AC 4417
Palmdale, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Nyblade, Dawn, Applicant, Statement of Issues Case SI 4675
Escondido, CA
Statement of Issues Case Filed 10/3/2013; Case Pending.
View the accusation

Opatz, Daniel, RPH 37645, Administrative Case AC 4788
Buena Park, CA
Accusation Filed 10/3/2013; Case Pending.
View the accusation

Orpilla, Michelle, Applicant, Statement of Issues Case SI 4844
Riverside, CA
Statement of Issues Filed 10/21/2013; Case Pending.
View the accusation

Ozimy, Eric, RPH 36956, Administrative Case AC 4746
Stockton, CA
Petition to Revoke Probation Filed 10/24/2013; Case Pending.
View the accusation

Perez, Jason, TCH 73032, Administrative Case AC 4481
Panorama City, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Poole, George, RPH 23729, Administrative Case AC 4528
Millbrae, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Rich, Edwin, TCH 4902, Administrative Case AC 4703
Pomona, CA
Accusation Filed 10/31/2013; Case Pending.
View the accusation

Romanolo, Lisa, RPH 37131, Administrative Case AC 4827
Prunedale, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Salas, Armando, TCH 127899, Administrative Case AC 4742
Corona, CA
Accusation Filed 10/3/2013; Case Pending.
View the accusation

Salinas-Sanchez, Jonathan, TCH 116074, Administrative Case AC 4739
Modesto, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Schmidt, Drahnier Del Rosario, TCH 122982, Administrative Case AC 4720
Arleta, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Shubin, Kathleen, TCH 35276, Administrative Case AC 4847
Santa Ana, CA
Accusation Filed 10/24/2013; Case Pending.
View the accusation

Simone, Jeffrey, RPH 62894, Administrative Case AC 4885
Santa Monica, CA
Accusation Filed 10/31/2013; Case Pending.
View the accusation

Soltero, Carlos, TCH 94675, Administrative Case AC 4768
El Monte, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Vaitai, Christina, TCH 105602, Administrative Case AC 4808
San Bruno, CA
Accusation Filed 21/2013; Case Pending.
View the accusation

Vergara, Crystal, TCH 108318, Administrative Case AC 4811
Ramona, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Waddle, Eric, Applicant, Statement of Issues Case SI 4596
Bakersfield, CA
Statement of Issues Filed 10/21/2013; Case Pending.
View the accusation

Yeung Wong, Angela Po-Chu, RPH 31278, Administrative Case AC 4496
San Francisco, CA
Accusation Filed 10/21/2013; Case Pending.
View the accusation

Zimmerman, William, RPH 37352, Administrative Case AC 4750
San Jose, CA
Petition to Revoke Probation Filed 10/3/2013; Case Pending.
View the accusation

California Board of Pharmacy November 14, 2013 webcast of meeting--including DISCUSSION AND POSSIBLE ACTION TO INITIATE A RULEMAKING TO AMEND TITLE 16 CALIFORNIA CODE OF REGULATIONS SECTIONS 1715, 1735.2 AND 1784, TO UPDATE THE SELF‐ASSESSMENT FORMS FOR PHARMACIES, HOSPITALS, WHOLESALERS AND COMPOUNDING PHARMACIES

November 14, 2013 Webcast

Department of Consumer Affairs 1625 N. Market Blvd. 1st Floor Hearing Room Sacramento, CA 95834

Agenda

Meeting Materials

Kudos to Michigan on taking action against pharmacist at Specialty Medicine Compounding Pharmacy

Judge Declines to Reinstate South Lyon Pharmacy's License

11/27/13 - The license suspension stands until at least January for a South Lyon pharmacy accused of mass-producing drugs for hospitals and clinics in violation of its license. The hearing was held yesterday before Administrative Law Judge David Cohen in Detroit, who ruled that the license suspensions of Specialty Medicine Compounding Pharmacy and its owner, Kenny Walkup Jr., will remain in place until at least January when a full hearing will take place. Attorney General Bill Schuette ordered the suspension after several of the pharmacy’s products at Henry Ford Hospital in Detroit were found to contain fungus. Tuesday’s hearing went late into the evening and hours of testimony centered on the whether or not the facility was sterile and whether Walkup and the pharmacy were licensed to mix products in bulk. The Detroit Free Press reports that inspectors for the state and the FDA testified that the pharmacy was not following proper procedures to ensure products were sterile. Walkup is said to have been acting as a drug manufacturer by distributing large amounts of medication to various hospitals and clinics even though the pharmacy is currently only licensed to fill individual prescriptions. He had applied for a license to manufacture drugs in October 2012, but that application was denied. Walkup’s attorney maintains that regulations allow pharmacists with that type of license to provide the service if it is less than 5% of the pharmacy’s business. A final decision will be made by the Michigan Pharmacy Disciplinary Subcommittee, which will be based on the judge’s recommendation. (JM)

quoted from here

Tarolimus Ointment v. Cyclosporine-- Compounded medications

Re: Tacrolimus Ointment.

Tacrolimus is a relative new drug to the veterinary world. It comes from a class of medications called "calcineurin inhibitors," and it is used most frequent for treating keratoconjunctivitis sicca (also known as KCS or dry-eye). Less commonly this medicine is used topically to treat for allergies (atopy) and for some of the autoimmune skin diseases (discoid lupus erythematosus, pemphigus erythematosus, etc.). In human medicine this medication is used orally for similar conditions at massively higher dosages.

The Most Dangerous Two Minute Sport--Doping in Horse Racing

by Michael Markarian, President of the Humane Society Legislative Fund — Our thanks to Michael Markarian for permission to republish this post, which originally appeared on his blog Animals & Politics on November 21, 2013. Racehorses are impressive, and it would be hard not to be awed by their power and grace. But there’s an important power they lack: unlike other athletes, they have no control over the drugs administered to them. That’s why groups such as The HSUS and HSLF and concerned legislators and citizens must be their voice. Horse race—image courtesy Humane Society Legislative FundThe House Subcommittee on Commerce, Manufacturing and Trade heard that voice today during a hearing on H.R. 2012, the Horseracing Integrity and Safety Act, a bill introduced by Reps. Joe Pitts, R-Pa., Ed Whitfield, R-Ky., Jan Schakowsky, D-Ill., and Anna Eshoo, D-Calif., to protect horses from pervasive race-day doping and other inhumane practices. (A companion bill, S. 973, is sponsored by Sen. Tom Udall, D-N.M.). The legislation would safeguard both the animal and human athletes who participate in the sport, as well as help the racing industry’s reputation recover from bad publicity about cheating and unfair - See more at: http://advocacy.britannica.com/blog/advocacy/2013/11/#sthash.fUr3sx4y.dpuf

Obamacare Winner: The Not-So-Hidden Industry Poised to Profit

Article Preview — For full access, register below, it's free

By Brian Orelli | More Articles
November 30, 2013 | Comments (0)

Drugmakers had to give up a big chunk of their profits when Obamacare, officially known as the Patient Protection and Affordable Care Act of 2010, was enacted. But the companies didn't seem to mind; well ahead of when the final law was written, the drug industry signed on to the law, giving seniors in Medicare Part D prescription coverage a discount on their drugs.
The rebates cover seniors as they hit the so-called doughnut hole after prescription drug coverage runs out but before catastrophic coverage kicks in. In the doughnut hole, senior were responsible for covering the full cost of their prescription drugs, but as part of Obamacare, the pharmaceutical industry agreed to offer seniors discounts.
For brand-name drugs, the discount started at 14% in 2012 and will eventually rise to 75% in 2020. Drugmakers with drugs that primarily treat seniors are disproportionally hurt by the legislation, but pretty much all drugmakers will end up losing profits from the discount to seniors. The only exceptions are drugs such as Dendreon's (NASDAQ: DNDN  ) Provenge and Regeneron Pharmaceuticals' (NASDAQ: REGN  ) Eyela that are administered by doctors because they're not covered by Medicare Part D.

Obamacare also increased …

Yet the drug industry was largely in favor of implementing Obamacare despite the discounts that cut into drugmakers profits.

Now we know whyAs was widely suspected, it appears the drug industry is going to benefit substantially from Obamacare in the long run.

The IMS Institute for Healthcare Informatics ran some scenarios, including a full implementation of Obamacare and a botched implementation leading to a significant decline in health-care utilization, and found that the difference between the two could be as much as $140 billion in 2017.

Under IMS's rosy scenario, drugmakers stand to profit from U.S. drug spending between $420 billion and $460 billion in 2017. Much of that gain comes from "increased enrollment, screening, removal of caps, and management of existing conditions."

In non-insurance speak, that's more patients, better diagnosis, no maximum payouts, and more spending on chronic diseases, which all leads to an increase in spending on drugs.

If Obamacare isn't instituted, the situation is much bleaker. Drugmakers will only share U.S. spending between $300 billion and $320 billion, which sounds like a lot, but it's actually a decline from the $328 billion Americans spent on drugs in 2012.

In the worst-case scenario, IMS predicts that drug spending will decline because insurers will push back on spending for new medications with premium prices.

Somewhere in the middleIMS's actual prediction is somewhere in the middle. The analysts predict U.S. drug sales will hit $350 million to $380 million in 2017, producing an annual compounded growth rate of 1% to 4% from 2012 levels. The prediction assumes a third of the target levels of enrollment in Obamacare by the uninsured and some pushback from insurers resulting in having drugmakers compete on price.

In that scenario, companies that are developing drugs that treat unmet needs -- Vertex Pharmaceuticals (NASDAQ: VRTX  ) in cystic fibrosis and Sarepta Therapeutics (NASDAQ: SRPT  ) in Duchenne muscular dystrophy for example, should be good investment because of a lack of competition and therefore pricing pressure.

Everything you need to know about ObamacareObamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." But don't hesitate, because it's not often that we release a free guide containing this much information and money-making advice. Please click here to access your free copy.

The Next Industry to Crumble...
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are perfectly positioned to take advantage of this game-changing economic shift. Enter your email address below to find out how YOU can take advantage!

Privacy/Legal Information

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

To keep reading, click here, it's free or login here

Eighth Question of the Day November 30, 2013 Because a number of pharmacies, pharmacists and organizations representing them advocated that states should retain jurisdiction over compounding pharmacies and the Drug Quality and Security Act (DQSA) leaves jurisdiction over traditional compounding with the states will these organziations now advocate to its members to comply with the states laws and will they support state boards of pharmacy who take a strong enforcement stance against those traditional compounderes who fail to comply?

Seventh Question of the Day November 30, 2013 Was there more the Colorado State Board of Pharmacy could have done in the NECC outbreak? Did it really do all that it could have? I do think it deserves kudos for what all it did do, but are there Colorado state criminal laws that were broken? I pose this question because IACP's position is someone like NECC would not register under the DQSA. Assuming this is true, then states need to be prepared to take more aggressive enforcement action in the future to stop another NECC outbreak.

In 2011, a year before the outbreak, the Colorado State Board of Pharmacy detected problems with the NECC when it was determined that the company was distributing compounded drugs in our state that had been manufactured ahead of time without first obtaining patient-specific prescriptions. This left Colorado patients at risk for being given a medication not appropriate for their specific medical needs and necessary health requirements.

Our state board issued a cease-and-desist order to the NECC, and notified the Massachusetts Board as well. But that was all it could do; ultimately, it was not enough to stop the NECC’s actions and prevent the tragic outbreak that swept across the nation a year later. Despite Colorado’s warnings, the state of Massachusetts did not act and, because it was hamstrung by existing regulations, the FDA could not act, either.

quoted from here

Sixth Question of the Day November 30, 2013 How many states other than Michigan on the NECC outbreak are preparing to bring state criminal charges against compounding pharmacies and pharmacists who the FDA found problems with and specially against those who have caused illnesses from bad compounds?

Fifth Question of the Day November 30, 2013 What will it ultimately take for state boards of pharmacy to be willing to enforce the laws on the books? The state employees who are charged with investing and enforcing these laws can only do so much? Ultimately if a state board dismisses the charges, allows minor fines etc., it does not matter how hard the state employees work to rein in rogue compounders. Are state boards of pharmacy preparing to step up their enforcement action? Are is it going to be business as usual with the states now that the Drug Quality and Security Act has become law? Is there a chance when Congress revisits the issue in 2014 it will take all the authority from the states if they have not stepped up enforcement action? Everyone is aware that Congress will be watching the FDA and its activity, but what happens if the FDA is doing what it is suppose to do and the local pharmacy, pharmacists and state boards are not?

Fourth Question of the Day November 30, 2013 How many state board members actually recuse themselves on matters which they have an ethical, personal or financial conflict of interest on compounding matters? Is this a violation of state law if they do not? If not, shouldn't it be?

Third Question of the Day November 30, 2013 How many members of state boards of pharmacy currently have conflicts of interest (personal, financial, or ethical) on compounding matters? Are state boards of pharmacy capable and willing to address these issues? Does the federal criminal system need to address these issues?

Second Question of the Day November 30, 2013 Will the Drug Quality and Security Act (DQSA) increase, decrease or have no effect on the corrpution in the industry?

Question of Day November 30, 2013 If compounding was already a 2 billion dollar business will the Drug Quality and Secuirty Act (DQSA) decrease or increase this number?

Animal Health Literacy Online Pet Pharmacies

Animal Health Literacy Online Pet Pharmacies

Wedgewood Pharmacy Pet and Veterinary Resources Provided

For Veterinary Practices

Prescribe Today About Order.WedgewoodPetRx.com Drug-Shortage and Back-Order Alert DeliverEase Dosage-Forms Refresh™ Expired Preparations Board Specialties Choosing a Compounding Pharmacy About PCAB Accreditation Printable Materials

For Pet and Horse Owners

How do I fill my new prescription? How much will my prescription cost? Pick Up or Refill a Prescription When Pets Won't Cooperate More Than 30 Available Flavors Dosage Forms Bitter-Block™ Gourmeds® Tasty, Chewable Tablets Low-dust Granules Medi-Melts® Medi-Mints™ Quad Tabs® Tiny Tabs® Pillable Tablets Twist-a-Dose® Transdermal Gel Applicator Twist-a-Taste® Oral Gel Applicator Facts About Compounding Share Your Pet Pictures

Learning Center

Resources for Veterinarians Professional Monographs About Order.WedgewoodPetRx.com Discussion Guide for Pet Owners and Veterinarians Medication Information for Pet and Horse Owners Articles for Pet and Horse Owners from PetMD® Articles for Pet and Horse Owners from VetVine® Twist-a-Dose Instructional Video Frequently Asked Questions

Key Report on the Veterinary Health Market Now available

11/29/13 - 2013 Report on the Veterinary Health Market
Dublin - Research and Markets (http://www.researchandmarkets.com/research/3x24vv/veterinary-health) has announced the addition of the "2013 Report on the Veterinary Health Market" report to their offering.
The range and complexity of animal health products continues to expand, encompassing anti-infectives, parasite controls, reproductive aids, metabolic drugs, feed additives, antibiotics, vaccines, topical solutions and imaging diagnostics as well as novel treatments for chronic conditions such as osteoarthritis, cardiovascular disease and even cancer.
This report also provides a thorough analysis of the companies known to be marketing, manufacturing or developing veterinary health products as well as detailed tables and figures covering veterinary health markets around the globe - including the following:
- Abaxis, Inc
- BASF
- Bayer Animal Health
- Boehringer Ingelheim Corp
- Cypress Diagnostics
- Dupont Qualicon
- Egyptian International Pharmaceutical Industries Company - Elanco Animal Health
- Gene Check, Inc
- Heska
- Huvepharma
- IWAKI & Co., Ltd
- Janssen Pharmaceutica
- Laboklin
- Merck
- Mosaic Company
- Neogen Corporation
- Novartis Animal Health
- OptiGen
- Orion Corporation
- Pfizer Animal Health
- Sanofi-Aventis
- Synbiotics Corporation
- Teva Pharmaceutical Industries Ltd
- VCA Antech, Inc
- Virbac SA
- WooGene B&G Co., Ltd
Key Topics Covered:
1. Overview
2. Animal Diseases: An Overview
3. Veterinary Medicines: An Overview
4. Global Livestock Production and Consumption: An Overview
5. Companion Animals: An Overview
6. Animal Health: Market Analysis
6.1 Role of Animal Health Industry
6.2 Evolution of Animal Health Market
6.3 Sub-Sectors of Animal Health Products
6.4 U.S. Veterinary Positions
6.5 U.S. Market for Veterinary Health
6.6 Veterinary Market in Brazil
6.7 Veterinary Market in Mexico
6.8 Animal Health Products Market in Europe
6.9 China's Booming Animal Health Domestic Market
6.10 Veterinary Market in India
6.11 Global Market for Veterinary Vaccines
6.12 U.S. Veterinary Vaccine Market
6.13 Veterinary Market for Companion Animals
6.14 U.S. Pet Care Market Trends
6.15 Expenditure on Companion Animals in Australia
6.16 Global Market for Animal Feed Additives
6.17 Global Market for Antibiotics in Animal Feeds
6.18 Exports of U.S. Micro-Ingredients and Supplements for Feed Additives 6.19 Global Market for Animal Feed Enzymes
6.20 Vitamins as Feed Additives
7. Company Profiles
For more information visit http://www.researchandmarkets.com/research/3x24vv/veterinary-health
CONTACT:
Research and Markets,
Laura Wood,
Senior Manager.
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Sector: Animal Healthcare/Veterinary (http://www.researchandmarkets.com/categories.asp?cat-id=346&campaign-id=3x24vv)

January 1st, 2012 Issued by: Rood and Riddle Equine Hospital Compounding Pharmacies: The Real Truth Bart Barber, DVM

“Being admitted to the profession of veterinary medicine, I solemnly swear to use my scientific knowledge and skills for the benefit of society through the protection of animal health [and] the relief of animal suffering…….” Veterinary oath

The ability of the veterinarian to relieve animal suffering has made enormous advances in the past 50 years. Our understanding of disease processes, the development and refinement of surgical technique and our diagnostic abilities have been vastly improved over recent decades. Imagine what James Herrriot would think of digital radiography or MRI. It’s a great day to be a veterinarian!

The advancement that has probably had the broadest affect is the improvement in our drug arsenal. Diseases that were death sentences for animals a few years ago are now cured by a few simple injections or a course of tablets. What can currently be done with pharmaceuticals is nothing short of a miracle. It seems certain that the greatest improvements that lie ahead of us will also come from this avenue.

One of the resources that we have for obtaining medications is through compounding. Compounding is defined as the manipulation of one or more drugs to form a new one. Many times an animal may require a medication that is not commercially available in the appropriate strength, in a flavor for maximum palatability, or a suitable method of administration. Compounding encompasses everything from something as simple as mixing two injections, to far more complex formulas. It is an essential part of our own human health care system as well as veterinary medicine. Without this resource many of the tools we have to combat disease and suffering would be unavailable to us and we would, in fact, be no better off than we were 50 years ago.

One truth in compounding is that not all compounding pharmacies are equal. Compounding pharmacies are not subject to the same oversight and regulations that drug manufacturers are. There have been some who, because of this lack of oversight, have produced compounded medications of poor standards, or have produced compounds to make a profit rather than to fill a legitimate need. These bad practices have given compounding in general a black eye. It has also left many wondering who they can trust and what is legal and ethical in compounding. The issues are broad and there are many interpretations. Those who are very familiar with compounding talk about the black and white issues as well as the gray ones. For the casual observer it can be very confusing and time consuming to sort out the issues.
continue to read here

Rood and Riddle Official Veterinary Pharmacy of Untied States Jumper Association

RRVP Official Veterinary Pharmacy of USHJA February 5th, 2013

Oklahoma Board of Pharmacy Update on Hydrocodone Refills

November 21, 2013

HYDROCODONE REFILL UPDATE (click to view full document):

• A pharmacy may partially fill a Hydrocodone prescription only if they are unable to supply the full quantity.  The remaining portion must be filled within 72 hours, and no further quantity may be supplied after that time without a new prescription.
• Pharmacies may partially fill Hydrocodone prescriptions for terminally ill patients and/or patients in a Long Term Care Facility (LTCF) for up to 60 days.  See OAC 475:30-1-7 for more detailed information about documentation.
• A Hydrocodone prescription may be transferred from one pharmacy to another only if it has never been filled at the original pharmacy (i.e. on hold).  Examples of this may be when a prescriber has sent the prescription to the wrong pharmacy or a pharmacy does not have the medication in stock.
• If a patient has a prescription for a certain quantity of Hydrocodone and their insurance will only pay for part of that prescription, they may pay cash for the remainder but it must occur within the same transaction and the pharmacist should document on the back of the prescription.
• The OBNDD has interpreted OAC 475:30-1-11 to mean that a prescriber may not write multiple prescriptions on the same date with instructions to fill some of those prescriptions at a later date.  This applies to Schedule II prescriptions as well as all other CDS prescriptions, including Hydrocodone.
• There is no legal limitation on the days’ supply for any CDS prescription.
• quoted from here

Stephen Thomas owner of Thomas Laboratories, Inc. and Arizonia Board of Pharmacy entered into consent agreement regarding records relating to veterinary drugs

W000174

Thomas Laboratories, Inc.

13-0006 CONSENT AGREEMENT

Arizonia Board of Pharmacy and Robert Eaton owner of Eaton Veterinary Laboratories Enter into Content Agreement Based on information from the Oklahoma Veterinary Board and Rimadyl

view consent decree here